Even though paroxysmal nocturnal hemoglobinuria (PNH) is rare, there are effective treatments—some of which can potentially cure the condition. However, the treatments have risks that people ...

A combination treatment has shown promise for treating a rare blood disease, according to a clinical trial published in the ...

Regeneron will have a tough job taking on AstraZeneca’s big-selling Ultomiris in the market for paroxysmal nocturnal haemoglobinuria (PNH) therapies – but new biomarker data suggests it could ...

Novartis’ targeted factor B inhibitor iptacopan has become the first oral monotherapy to be approved by the FDA for rare blood disorder paroxysmal nocturnal haemoglobinuria (PNH). The drug ...

On the instructions of Rameau Normil, Acting Director General of the National Police of Haiti (PNH), Divisional Commissioner ...

Eculizumab biosimilar Elizaria demonstrates long-term safety and efficacy comparable with the reference product Soliris in ...